In reaction to AbbVie’s massive acquisition of Pharmacyclics, investors who were caught unprepared are looking for ways they could have predicted the deal. Casey McDonald looks at the reaction on Twitter.
We’re staying tuned to the twittersphere. Here’s another list of some top tweets from the last few weeks. If you have suggestions for more, please send them, or tweet @PharmExecutive or use #PharmExecTopTweets
In reaction to AbbVie’s massive acquisition of Pharmacyclics, investors who were caught unprepared are looking for ways they could have predicted the deal.
A “tell” re $ABBV- $PCYC that everyone missed: ABBV pulled out of the Cowen conference yesterday.
- Roy Friedman (@DewDiligence) March 5, 2015
But maybe this isn’t a completely reliable tell of a company in late negotiations for a $21bn takeover. Especially with the winter we’re having on the east cost, a lot of cancellations have been due to the weather, as @AndyBiotech points out. There were plenty more articles and tweets on this deal:
@AntoineGara at Forbes called it a red flag for the sector:
For vocal hedge funds, who in many ways are the architects of today’s dealmaking, the risk of a bust looms large http://t.co/HDmVYgqDLT
While WSJ’s Jonathan Rockoff quotes AbbVie CEO Richard Gonzalez saying that three companies bid til the end in “one of the most competitive” bidding wars he’s ever seen:
AbbVie CEO says 3 cos were bidding for $PCYC till very end. "One of the most competitive" pharma sales ever. http://t.co/sxRYOUcmW6@WSJ
- Jeanne Whalen (@JeanneWhalen) March 5, 2015
Peter D. @Loftus noted that AbbVie’s projections justifying the deal might be a tad grand.
AbbVie CEO throws out huge sales numbers to justify Pharmacyclics price tag - peak Imbruvica sales $7B! Peak ABBV oncology sales $15B!
- Peter D. Loftus (@Loftus) March 5, 2015
A potential setback for biosimilars coming to the US, in late February, the FDA postponed a much anticipated meeting, originally scheduled for March 17. What this means for Celltrion and Hospira’s Remsima is unclear. Reasons for the postponement are unclear and we’ve yet to see a new date for the meeting. We wonder if they just decided they didn’t want to meet on St. Patrick’s day.
#FDA postpones key hearing on #biosimilar copy of blockbuster drug - panel on #Celltrion's #Remsima was due March 17 http://t.co/EUZvedzqCy
- Ben Hirschler (@reutersBenHir) February 26, 2015
In other news, showing that its plan to offer genomic testing direct-to-consumer is progressing, 23andMe tweeted its major announcement in February. The company will now market a test for Bloom Syndrome Carrier Status. The news was quite significant and shows that the FDA will allow it to proceed, with proper evidence and likely in a stepwise fashion.
First of its kind DTC genetic test granted marketing authority by @US_FDA for our Bloom Syndrome Carrier Status test. http://t.co/BMlaM5jxBm
- 23andMe (@23andMe) February 20, 2015
Earlier in February, there were several good tweets from BIO’s BIOCEO conference, #BIOCEO15. When Pfizer CEO Ian Read speaks, people listen. Several were taken by his comments that the insurance system, as it is now, is not set up to pay for cures.
Read: "Insurance plans are not set up for cures; they're set up for chronic disease. Can't calculate value of cure." #BIOCEO15
- Wayne Koberstein (@WayneKoberstein) February 10, 2015
"Insurance models aren't set up to pay for cures. They're set up to pay for chronic disease," $PFE CEO Ian Read says at #BIOCEO15
- Meg Tirrell (@megtirrell) February 10, 2015
Also at #BIOCEO15
Overheard twice today at #BIOCEO15: "...we're going to be starting up a CAR-T company."
- Brad Loncar (@bradloncar) February 10, 2015
And in a rare appearance, Gilead’s COO John Milligan spoke at BIOCEO:
#BIOCEO15 Barclay's analyst Geoff Meacham gets right to it with $GILD's MIlligan - no intro, just a pricing question
- Chris Morrison (@CT_Morrison) February 10, 2015
Milligan: Only 3 yrs ago, we closed Pharmasset deal. Intro'd Sovaldi, then made it obsolete w Harvoni. Put stress on the org #BIOCEO15
- Luke Timmerman (@ldtimmerman) February 10, 2015
And John Maraganore, Alnyam’s CEO on developing RNAi delivery:
"It was sort of a Manhattan project" says $ALNY's JM. #BIOCEO15 $75M a year, collaboration with MIT's Langer. Broad investment in delivery.
- Matthew Herper (@matthewherper) February 10, 2015
Asembia 2025: Therapy Advancements Highlight Growing Cost and Access Concerns
April 30th 2025Fran Gregory, VP, emerging therapies, Cardinal Health, discusses the evolving cell and gene therapy landscape, highlighting pipeline growth, cost challenges, and emerging therapeutic areas beyond oncology and hematology.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
FDA Approves AbbVie’s Rinvoq as First Oral JAK Inhibitor for Giant Cell Arteritis
April 30th 2025AbbVie secures FDA approval for Rinvoq as the first oral Janus kinase inhibitor indicated for giant cell arteritis, expanding its immunology portfolio and signaling strategic growth opportunities in underserved autoimmune markets.